|
|
| | Butanedioic acid, compd. with N-[(3-endo)-8-[[4-(thiazolo[4,5-b]pyridin-2-yloxy)phenyl]methyl]-8-azabicyclo[3.2.1]oct-3-yl]acetamide (1:) Basic information |
| | Butanedioic acid, compd. with N-[(3-endo)-8-[[4-(thiazolo[4,5-b]pyridin-2-yloxy)phenyl]methyl]-8-azabicyclo[3.2.1]oct-3-yl]acetamide (1:) Chemical Properties |
| | Butanedioic acid, compd. with N-[(3-endo)-8-[[4-(thiazolo[4,5-b]pyridin-2-yloxy)phenyl]methyl]-8-azabicyclo[3.2.1]oct-3-yl]acetamide (1:) Usage And Synthesis |
| Uses | JNJ-40929837 succinate is a selective and orally active LTA4H (leukotriene A4 hydrolase) inhibitor. JNJ-40929837 succinate effectively inhibits aminopeptidase activity and causes serum accumulation of Pro-Gly-Pro. JNJ-40929837 succinate can be used in asthma research[1]. | | References | [1] Low CM, et al. The development of novel LTA4H modulators to selectively target LTB4 generation. Sci Rep. 2017 Mar 17;7:44449. DOI:10.1038/srep44449 |
| | Butanedioic acid, compd. with N-[(3-endo)-8-[[4-(thiazolo[4,5-b]pyridin-2-yloxy)phenyl]methyl]-8-azabicyclo[3.2.1]oct-3-yl]acetamide (1:) Preparation Products And Raw materials |
|